UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/598,336	09/25/2007	Konrad Kemper	2400.0740000/RWE/DAS	2752
	7590 10/05/201 SLER, GOLDSTEIN &	EXAMINER		
1100 NEW YO	RK AVENUE, N.W.	BROWN, COURTNEY A		
WASHINGTON, DC 20005			ART UNIT	PAPER NUMBER
			1617	
			MAIL DATE	DELIVERY MODE
			10/05/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/598,336	KEMPER ET AL.		
Examiner	Art Unit		
COURTNEY BROWN	1617		

	COURTNEY BROWN	1617	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>16 September 2010</u> FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	replies: (1) an amendment, affidavit eal (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
 a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this Among event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f) 	dvisory Action, or (2) the date set forth inter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE ().	g date of the final rejectio FIRST REPLY WAS FIL	n. .ED WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extra under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of the hortened statutory period for reply original for the hortened statutory period for reply original for the hortened statutory period for reply original for the hortened statutory and the hortened	of the fee. The appropria nally set in the final Offic	ite extension fee e action; or (2) as
 The Notice of Appeal was filed on A brief in complifiling the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
 The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further cor (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in better the content of the proposed forms. 	nsideration and/or search (see NOT w);	TE below);	
appeal; and/or (d) They present additional claims without canceling a converse NOTE: (See 37 CFR 1.116 and 41.33(a)).			ie issues ioi
4. The amendments are not in compliance with 37 CFR 1.12	21. See attached Notice of Non-Cor	mpliant Amendment (F	PTOL-324).
5. Applicant's reply has overcome the following rejection(s):			
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 		•	
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 14 and 16. Claim(s) withdrawn from consideration:		l be entered and an ex	planation of
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 	l sufficient reasons why the affidavi	t or other evidence is	necessary and
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	ll and/or appellant fails	to provide a
 10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been consideration because: See Continuation Sheet. 		•	
12. ☐ Note the attached Information <i>Disclosure Statement</i> (s). (13. ☐ Other:	PTO/SB/08) Paper No(s)		
/Fereydoun G Sajjadi/ Supervisory Patent Examiner, Art Unit 1617			

Continuation of 11. does NOT place the application in condition for allowance because: . The examiner maintains the rejection of claims 14 and 16 under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Asrar et al. (US Patent 7,098,170 B2,) for reasons of record. Applicant's arguments have been fully considered, but are not found persuasive. Applicant argues that the Examiner failed to give weight to the "material acted upon," i.e., soya bean plants subject to subsequent attack byphytopathogenic fungi. Applicant argues that Asrar et al. does not disclose protecting plants subject to subsequent attack by phytopathogenic fungi. Rather, Applicant argues that Asrar et al. focuses solely on increasing the yield and/or vigor of plants in the absence of pest pressure by fugal plant pathogens. Thus, Applicant argues that the material acted upon in Asrar et al. is not the same that that of the current claims and the Examiner has failed to give weight to this difference. However, the Examiner maintains the position that Asrar et al. disclose all the limitations of the instant claims wherein soybean and seed are treated with fluquinconazole alone and/or in combined with azoxystrobin which inherently protects the soybean from soybean rust. Ansar et al. specifically teach the step of treating soybean plant or its seed with fluquinconazole. Thus, the "material acted upon" is the same. The fact that that the plant or seed are subsequently protected against a fungal plant pathogen is an outcome that necessarily results from said treatment. Thus, the rejection is maintained for reasons of record and the foregoing commentary. No new or amended claims have been submitted.

Any inquiry concerning the rejection of claims 14 and 16, refer to the Final rejection, mailed on June 24, 2010.

Claims 14 and 16 remain rejected.